Last updated on January 2019

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B


Brief description of study

The purpose of the current Phase 1/2a single dose, dose-escalating study is to evaluate the acute safety, pharmacokinetics (PK) and pharmacodynamics (PD) properties of MOD-5014 in adult subjects with moderate/severe congenital hemophilia A or B. This will be a single-dose, open label, dose-escalating study. Each dose cohort will be concluded by a safety review, following which escalation to the next dose cohort will be approved.

Clinical Study Identifier: NCT02418793

Contact Investigators or Research Sites near you

Start Over

City of Hope

Duarte, CA United States

Children's Hospital Los Angeles

Los Angeles, CA United States

Orthopaedic Hemophilia Treatment Center

Los Angeles, CA United States

University of California Davis Medical Center

Sacramento, CA United States

Rush University Medical Center

Chicago, IL United States

Bleeding & Clotting Disorders Institute

Peoria, IL United States

Indiana Hemophilia & Thrombosis Center

Indianapolis, IN United States

UPMC Presbyterian Shadyside

Pittsburgh, PA United States

UT Southwestern Medical Center

Dallas, TX United States

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.